Join us for a practical and empowering discussion about current treatment options for follicular lymphoma (FL). Whether you’re newly diagnosed or considering your next steps, this session will help you better understand potential options and how to navigate the decision-making process.
Date: Thursday 5 June 2025
Time: 5.30pm–6.30pm BST / 9.30am-10.30am PDT / 12.30–1.30pm EDT
🎥 Free + Open to everyone! Whether you’re living with FL, a family member, caregiver, or healthcare professional, this webinar will provide valuable knowledge and an inspiring personal story
What we’ll cover:
Why attend?
Don’t miss this opportunity to engage, learn, and ask your questions on FL treatment options.
Stay tuned for more webinars covering other highly requested topics in the coming months!
Dr Mitchell Smith – Chief Medical Officer, Follicular Lymphoma Foundation
Dr Mitchell Smith has an extensive educational background, having earned his Medical Degree and PhD from Case Western Reserve University School of Medicine in Cleveland, OH. He has also completed several residencies and fellowships, including a Fellowship in Medical Oncology at Memorial Sloan-Kettering Cancer Centre in NY. Dr Smith’s career has also spanned many years and institutions, including serving as Director of the Lymphoma Program at Fox Chase Cancer Centre and Director of the Lymphoid Malignancy Program at the Cleveland Clinic. Join him as he shares his expert insights throughout our engaging webinar series.
Professor Andrew Davies – Professor of Haematological Oncology, University Hospital Southampton
Andrew Davies is Professor of Haematological Oncology in the Cancer Sciences Unit in the Faculty of Medicine, University Hospital Southampton. He completed his training in Medical Oncology at St Bartholomew’s Hospital in London, and as a Cancer Research UK clinical fellow he undertook a PhD examining the molecular mechanisms underlying transformation of follicular lymphoma to more aggressive histological sub-types.
Prof. Davies specialises in the treatment of malignant lymphoma. He has a particular interest in the investigation of novel therapeutics applied to lymphoma. He has extensive experience in early phase trials, including leading several first in man lymphoma studies all the way through to leading late phase studies.
He is Chair of the UK Lymphoma Research Network. He is Director of the Cancer Research UK/National Institute of Health Southampton Experimental Cancer Medicine Centre. He is also the Wessex regional lead for cancers in Teenagers and Young Adults (TYA) and Clinical Lead for the Thames Valley and Wessex TYA Operational Delivery Network.
Bob McEachern (aka Lympho Bob), Patient Advocate
Bob was diagnosed with stage 3, grade 1/2 follicular lymphoma in 2008 at age 40. The diagnosis was confusing, since he was in the best shape of his life (he ran a personal best in a 5k road race two weeks after he was diagnosed). After blood tests, scans, and consultation with two oncologists, Bob was able to watch and wait. Two years to the day after his diagnosis, he started rituximab monotherapy, made necessary by swelling in his leg. Despite not having a clean scan in 17 years, he has not needed further treatment, since his FL has remained stable. He dedicates some of his free time as a patient advocate, writing about follicular lymphoma and representing other FL patients.
This webinar is intended for educational and disease awareness purposes only and the information presented and discussed does not constitute medical advice.
This webinar series is supported by an educational grant from Genmab US, Inc and AbbVie and sponsorship from BeiGene USA, Inc., and Novartis. All of the above have had no influence on, control of, nor input into the development or performance of the webinar series.
